Vico Therapeutics develops RNA modulation therapies using antisense oligonucleotides to target genetic neurological disorders, specifically focusing on conditions like Huntington's disease and spinocerebellar ataxia. Their VICOMER™ platform enables allele-preferential targeting of CAG repeat expansions, providing a reversible and transient treatment approach without altering DNA.
Funding
$101.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Genetic neurological disorders, such as Huntington's disease and spinocerebellar ataxia, often lack effective treatments that address the underlying genetic cause of the disease. Current therapeutic options may only manage symptoms without targeting the mutated genes responsible for disease progression. This leaves a significant unmet need for therapies that can selectively modulate gene expression to alleviate the effects of these debilitating conditions.
Solution
Vico Therapeutics is developing RNA modulation therapies using antisense oligonucleotides to target genetic neurological disorders. Their VICOMER™ platform enables allele-preferential targeting of CAG repeat expansions, a common mutation found in diseases like Huntington's disease and spinocerebellar ataxia. This approach allows for selective silencing of the disease-causing allele while preserving the function of the healthy allele. The resulting therapeutic effect is reversible and transient, providing a controlled and adaptable treatment strategy without permanently altering the patient's DNA. By modulating RNA, Vico Therapeutics aims to address the root cause of these disorders and improve patient outcomes.
Target Audience
The primary target audience includes patients suffering from genetic neurological disorders, such as Huntington's disease and spinocerebellar ataxia, as well as the healthcare professionals who treat them.
Features
- VICOMER™ platform for designing RNA modulating therapeutics
- Allele-preferential targeting of CAG repeat expansions
- Antisense oligonucleotide-based approach for selective gene silencing
- Reversible and transient therapeutic effect
- Does not alter DNA code
- Focus on genetic neurological disorders